2023 - Research.com Medicine in Norway Leader Award
2022 - Research.com Medicine in Norway Leader Award
His primary areas of study are Internal medicine, Homocysteine, Endocrinology, Risk factor and B vitamins. Per Magne Ueland combines subjects such as Gastroenterology and Methylenetetrahydrofolate reductase with his study of Internal medicine. Per Magne Ueland usually deals with Gastroenterology and limits it to topics linked to Myocardial infarction and Coronary artery disease.
The Homocysteine study combines topics in areas such as Vitamin and Prospective cohort study, Surgery. His Endocrinology research is multidisciplinary, incorporating perspectives in Antiestrogen, Tamoxifen and Disease. His Risk factor study combines topics from a wide range of disciplines, such as Diabetes mellitus, Epidemiology, Vascular disease and Cardiology.
The scientist’s investigation covers issues in Internal medicine, Endocrinology, Homocysteine, Biochemistry and B vitamins. He regularly ties together related areas like Gastroenterology in his Internal medicine studies. The various areas that Per Magne Ueland examines in his Endocrinology study include Pyridoxal, Dimethylglycine and Kynurenine.
His Homocysteine study integrates concerns from other disciplines, such as Cobalamin, Risk factor, Methylenetetrahydrofolate reductase and Methionine. In his research on the topic of Cobalamin, Pregnancy is strongly related with Physiology. His Biochemistry research incorporates themes from Molecular biology and Chromatography.
Per Magne Ueland mainly focuses on Internal medicine, Endocrinology, Prospective cohort study, Neopterin and Vitamin. His studies deal with areas such as Gastroenterology and Oncology as well as Internal medicine. His Endocrinology research focuses on Dimethylglycine and how it relates to Choline.
His work deals with themes such as Cystathionine beta synthase, Vitamin D and neurology, Food science and Homocysteine, which intersect with Vitamin. His research on Homocysteine often connects related areas such as Methylenetetrahydrofolate reductase. His Case-control study research is multidisciplinary, incorporating perspectives in Odds ratio and B vitamins.
Per Magne Ueland mostly deals with Internal medicine, Cohort, Prospective cohort study, Case-control study and Vitamin. His studies deal with areas such as Gastroenterology, Endocrinology, Oncology and Kynurenine as well as Internal medicine. His Cohort research is multidisciplinary, incorporating elements of Pregnancy, Cotinine, Cohort study and Atrial fibrillation.
His research investigates the link between Prospective cohort study and topics such as Odds ratio that cross with problems in Large cell and C-reactive protein. The various areas that Per Magne Ueland examines in his Case-control study study include Lung cancer and Pyridoxal. His work in Heart disease covers topics such as Transsulfuration which are related to areas like Homocysteine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project.
Graham Im;Daly Le;Refsum Hm;Robinson K.
JAMA (1997)
Homocysteine and Cardiovascular Disease
H. Refsum;P. M. Ueland;O. Nygård;S. E. Vollset.
Annual Review of Medicine (1998)
Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis
R. Clarke;R. Collins;S. Lewington;A. Donald.
JAMA (2002)
Plasma Homocysteine Levels and Mortality in Patients with Coronary Artery Disease
Ottar Nygård;Jan Erik Nordrehaug;Helga Refsum;Per Magne Ueland.
The New England Journal of Medicine (1997)
Folate, Vitamin B12, and Serum Total Homocysteine Levels in Confirmed Alzheimer Disease
R Clarke;A D Smith;K A Jobst;H Refsum.
JAMA Neurology (1998)
Homocysteine lowering and cardiovascular events after acute myocardial infarction.
Kaare Harald Bønaa;Inger Njølstad;Per Magne Ueland;Henrik Schirmer.
The New England Journal of Medicine (2006)
Total homocysteine in plasma or serum: methods and clinical applications.
P M Ueland;H Refsum;S P Stabler;M R Malinow.
Clinical Chemistry (1993)
Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study.
O Nygård;S E Vollset;H Refsum;I Stensvold.
JAMA (1995)
Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men
I.J. Perry;R.W. Morris;S.B. Ebrahim;A.G. Shaper.
The Lancet (1995)
Facts and Recommendations about Total Homocysteine Determinations: An Expert Opinion
Helga Refsum;A. David Smith;Per M. Ueland;Ebba Nexo.
Clinical Chemistry (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Oslo
University of Washington
University of Bergen
University of Paris-Saclay
Utrecht University
Imperial College London
National and Kapodistrian University of Athens
National and Kapodistrian University of Athens
University of Bergen
International Agency For Research On Cancer
Carnegie Mellon University
University of California, San Diego
Beihang University
University of Catania
University of Macau
Max Delbrück Center for Molecular Medicine
University of Glasgow
Radboud University Nijmegen
University of Erlangen-Nuremberg
Friedrich-Loeffler-Institut
University of South Carolina
Leibniz Association
Université Paris Cité
University Health Network
Karolinska Institute
University of California, Santa Barbara